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Abstract
Background: Dupuytren’s disease is an inherited disorder in which patients develop fibrotic contractures of the hand.
Current treatment strategies include surgical excision or enzymatic digestion of fibrotic tissue. MicroRNAs, which are
key posttranscriptional regulators of genes expression, have been shown to play an important regulatory role in
disorders of fibrosis. Therefore in this investigation, we apply high throughput next generation RNA sequencing
strategies to characterize microRNA expression in diseased and healthy palmar fascia to elucidate molecular
mechanisms responsible for pathogenic fibrosis.
Methods: We applied high throughput RNA sequencing techniques to quantify the expression of all known human
microRNAs in Dupuytren’s and control palmar fascia. MicroRNAs that were differentially expressed between diseased
and healthy tissue samples were used for computational target prediction using the bioinformatics tool ComiR.
Molecular pathways that were predicted to be differentially expressed based on computational analysis were
validated by performing RT-qPCR on RNA extracted from diseased and non-diseased palmar fascia biopsies.
Results: A comparison of microRNAs expressed in Dupuytren’s fascia and control fascia identified 74 microRNAs with a
2-fold enrichment in Dupuytren’s tissue, and 32 microRNAs with enrichment in control fascia. Computational target
prediction for differentially expressed microRNAs indicated preferential targeting of collagens and extracellular matrix
related proteins in control palmar fascia. RT-qPCR confirmed the decreased expression of microRNA targeted collagens
in control palmar fascia tissues.
Discussion: Control palmar fascia show decreased expression of mRNAs encoding collagens that are preferentially
targeted by microRNAs enriched in non-diseased fascia. Thus alterations in microRNA regulatory networks may play an
important role in driving the pathogenic fibrosis seen in Dupuytren’s disease via direct regulatory effects on
extracellular matrix protein synthesis.
Conclusion: Dupuytren’s fascia and healthy palmar fascia can be distinguished by unique microRNA profiles, which are
predicted to preferentially target collagens and other extracellular matrix proteins.
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Background
Dupuytren’s disease is a clinically challenging disorder
characterized by the formation of fibrotic bands that
cause disabling contractures of the hand. If the disease is
not treated, fibrosis can lead to significant functional
limitations that may even necessitate amputation of the
affected fingers. Current treatment strategies attempt to
break up constrictive bands of fibrous tissue after colla-
gen deposition either surgically or enzymatically with
collagenase. These treatments are costly and carry a sig-
nificant complication risk and are associated with a high
rate of disease recurrence [1–5].
Dupuytren’s disease has a strong genetic basis and most
commonly affects individuals of northern European des-
cent [6]. Large scale genome wide association studies have
helped improve our understanding of Dupuytren’s disease,
however the specific genetic abnormalities that drive
disease pathogenesis have remained elusive. A variety of
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molecular pathways have been implicated in disease patho-
genesis including alterations in Wnt signaling and mito-
chondrial genes [7–9].
MicroRNAs, which are small non-coding RNA mole-
cules (20–24 nucleotides in length) that act as post tran-
scriptional regulators of gene expression by inhibiting
the translation of target mRNAs, have been shown to
regulate the expression of extracellular matrix proteins
in the setting of fibrosis [10–13]. Given that Dupuytren’s
disease is characterized by excess collagen deposition
and fibrosis, we examined the role of microRNAs as
pro-fibrotic drivers of the disease process. In this investi-
gation we applied high throughput molecular sequencing
techniques to characterize all known microRNAs expressed
in diseased Dupuytren’s fascia, and compared expression
profiles to non-diseased palmar fascia. We also utilized
differentially expressed microRNAs to identify novel path-




Dupuytren’s tissue biopsies were collected for research use
from patient’s undergoing open palmar fasciectomy for the
treatment of Dupuytren’s contracture. Surgical cases clinic-
ally represented end stage disease in the consolidation
phase. All Dupuytren’s tissue specimens were evaluated
under frozen section by trained musculoskeletal patholo-
gists to confirm the diagnosis and to ensure representative
areas of diseased tissue were selected. Samples were then
snap frozen in liquid nitrogen and stored at −80 °C until
use for RNA extraction. Adjacent fascia specimens were
obtained from palmar fascia adjacent to diseased Dupuyt-
ren’s fascia that was deemed to be normal clinically based
upon intraoperative inspection under loupe magnification.
To avoid unnecessary risk to patients, adjacent fascia was
only collected for research use when sufficient quantities of
adjacent tissue were removed during the normal course of
surgery, additional surgical procedures were not performed
to acquire adjacent fascia. Control palmar fascia biopsies
were obtained from healthy patients without a history of
Dupuytren’s disease undergoing open carpal tunnel release.
Specifically, a small section (~1 cm x 1 cm) of palmar
fascia located just superficial to the transverse carpal
ligament was collected. The specimen was snap frozen
in liquid nitrogen, followed by storage at −80 °C until
use for molecular analysis. In total, 25 tissue samples
were collected and used for high resolution molecular
analysis. There were 15 diseased Dupuytren’s fascia bi-
opsies, seven external controls biopsies, and three adja-
cent fascia specimens. Informed consent was obtained
under institutional review board approved protocols for
all specimens used in this investigation (Genetic analysis
of disorders of fibrosis IRB # 12–000208).
Fig. 1 MicroRNA sequencing reads are shown plotted on a linear (top) and log scale (bottom) for both Dupuytren’s and control palmar fascia
tissue samples. These plots show that the top 100 most highly expressed microRNAs account for greater than 90 % of the total sequence reads.
Thus, a small subset of microRNAs are expressed at a much higher levels than all the remaining human microRNAs, and may have a greater
functional impact on cell activity
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Fig. 2 (See legend on next page.)
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RNA extraction
Tissue biopsies were frozen using liquid nitrogen and
ground into a powder using a mortar and pestle. Crushed
samples were placed into Qiazol reagent and homogenized
using the TissueLyser LT (Qiagen, Hilden, Germany).
MicroRNAs were extracted from research biopsies using
the miRNeasy minikit (Qiagen, Hilden, Germany). Total
RNA was quantified using the NanoDrop 2000 spectro-
photometer (Thermo Fischer Scientific, Wilmington,
Delaware).
RNA Sequencing (RNA-seq) and bioinformatics analysis
MicroRNAs were sequenced using the NEBNext Small
RNA library prep kit on an Illumina HiSeq 2000. The
short reads were trimmed of adapters with Cutadapt
[14]. Trimmed microRNA sequences greater than 17
nucleotides in length were then aligned to the reference
genome and miRBase reference sequences using Bowtie
[15]. Known microRNA expression and novel microRNA
prediction and quantification were performed with miR-
Deep2 [16], using the CAP-miRSeq analysis pipeline [17].
Unsupervised hierarchical clustering was performed using
the Pearson correlation method. ComiR, a computational
tool for combinatorial microRNA target prediction was
used to identify molecular pathways regulated by micro-
RNAs that were differentially expressed between diseased
and non-diseased palmar fascia [18, 19]. The Database for
Annotation and Visualization and Integrated Discovery
v6.7 (DAVID 6.7) [20, 21] was used to characterize func-
tional gene clusters regulated by microRNA target genes.
RT-qPCR validation
The activity of pro-fibrotic pathways, including the Wnt
and TGFβ signaling pathways, were assessed by measuring
the expression of regulatory mRNAs using real-time
quantitative polymerase chain reaction (RT-qPCR). Total
RNA from 11 Dupuytren’s specimens and seven control
biopsies, which were previously used for small RNA-seq,
were used for cDNA synthesis. Reverse transcription and
RT-qPCR reactions were performed as previously de-
scribed by Dudakovic et al. [22]. Transcript levels were
normalized to AKT1, because this gene is most consist-
ently expressed across samples within the mesenchymal
lineage compared to other conventional housekeeping
genes including GAPDH, HPRT and ACTB based on data
we obtained for >400 different mesenchymal cell types
(See figure on previous page.)
Fig. 2 Unsupervised hierarchical clustering of comprehensive microRNA sequencing reads using the Pearson correlation method results in independent
clustering of Dupuytren’s and control palmar fascia. Only a single adjacent fascia specimen clustered with the Dupuytren’s fascia indicating that visual
inspection alone may not be reliable in distinguishing between diseased and non-diseased fascia. These data show that microRNA expression patterns
may be able to differentiate between diseased and non-diseased fascia and may play key roles in driving pathogenic fibrosis
Fig. 3 A comparison of the absolute number of microRNAs and corresponding sequencing reads enriched in Dupuytren’s versus control fascia for
abundantly expressed microRNAs (microRNAs expressed at more than 100 normalized reads per million). These data show that Dupuytren’s tissue has
greater enrichment in different types of microRNAs (a) as well as the absolute number of microRNAs based on normalized read count (b)
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and musculoskeletal tissues (SMR & AJvW, unpublished
data). Gene expression levels were quantified using the
2-ΔΔCt method. Differences in gene expression between
diseased and control samples were evaluated using a two-
tailed student’s t-test. Error bars are shown as the mean ±
one standard deviation statistical significance was set at
p < 0.05 and is indicated by (*). Primer sequences are
given in (Additional file 1: Table S1).
Results
RNA-seq evaluation
In this investigation we applied high throughput next
generation RNA-seq to quantify the expression of all
known human microRNAs (N = 2252) to understand
their roles in the pathogenesis of Dupuytren’s disease.
Initial sequencing results showed that more than 99 % of
the sequencing reads averaged across all Dupuytren’s
and control samples were represented by the top 100
most abundantly expressed microRNAs (Fig. 1). This
distribution is consistent across both the diseased and
control tissues, and shows that a relatively small subset
of all known human microRNAs account for the major-
ity of microRNAs expressed in palmar fascia biopsies.
These abundant microRNAs may therefore play a more
important functional role in regulating cellular processes
connected to Dupuytren’s disease pathogenesis than
microRNAs with low levels of expression.
Unsupervised hierarchical clustering was performed
using the Pearson correlation method to provide an un-
biased assessment of the ability of microRNAs to differen-
tiate between diseased and non-diseased palmar fascia
biopsies (Fig. 2). The clustering dendrogram showed inde-
pendent grouping of the control and diseased palmar
fascia biopsies. There was only a single adjacent fascia
biopsy that clustered with the Dupuytren’s specimens sug-
gesting that this specimen may have in fact been diseased
tissue that appeared grossly normal intra-operatively.
To identify specific microRNAs with a functional role
in the pathogenesis of Dupuytren’s disease we made a fold
change comparison of microRNA profiles in Dupuytren’s
biopsies against control samples (excluding adjacent
fascia). In the comparison of Dupuytren’s fascia and con-
trol fascia we identified 74 microRNAs with a statistically
significant 2-fold enrichment in Dupuytren’s tissue, and
32 microRNAs with a statistically significant enrichment
in control fascia (Additional file 2: Table S2). The diseased
Dupuytren’s fascia show enrichment (fold change > 2) in a
greater variety of different microRNAs compared with
control fascia (Fig. 3a), and an even larger increase in the
overall number of microRNA sequencing reads (Fig. 3b).
To determine if the differentially expressed sequencing
reads were being generated by a large number of different
microRNAs, or a focused group of microRNAs we exam-
ined the distribution of differentially expressed microRNA
sequencing reads. The majority of the differentially
expressed microRNA reads were found to be concentrated
amongst a relatively small group of differentially expressed
microRNAs (Fig. 4). Notably the microRNAs upregulated
in the control fascia accounting for the greatest differential
in read count are heavily enriched in previously validated
anti-fibrotic extracellular matrix targeting microRNAs
(Table 1), including let-7 [23–25], miR-29a-3p [26], miR-
26b-5p, miR-30d-5p [27, 28], miR-27a-3p, miR-27b-3p
[29, 30], miR-10a-5p [31], miR-26a-5p [32–35], miR-101-
3p [36–39], and miR-10b-5p [40], as well as anti-
proliferative microRNAs including, miR-126-3p [41–47],
miR-99a-5p [48–54], miR-125a-5p [55–59], and miR-139-
5p [60–62]. MicroRNAs enriched in Dupuytren’s fascia
target appear to target a diverse array of functional path-
ways. miR-21-5p is an established oncomiR that promotes
cellular proliferation in cancer [63–65]. miR-210 is a
known hypoxia inducible, fibrosis promoting microRNA
that may be associated with decreased tissue perfusion in
Dupuytren’s cords [66, 67]. These findings suggest that a
relatively small group of microRNAs with large differences
in expression act to selectively target molecular pathways
regulating tissue fibrosis.
To determine if adjacent fascia exhibits a disease-like
molecular phenotype, we compared the adjacent fascia
biopsies with patient matched diseased Dupuytren’s
fascia. A direct comparison of the three matched adjacent
Fig. 4 To identify the microRNAs with the greatest functional impact on
fibrosis, we examined which microRNAs show the greatest difference in
sequencing reads between diseased Dupuytren’s fascia and control
fascia regardless of fold change. This analysis, comparing all statistically
significant differentially expressed microRNAs with an average expression
greater than 100 normalized reads, shows that a small subset of
differentially expressed microRNAs account for the majority of
sequencing reads. These microRNAs, which show the greatest
change in abundance, may potentially make the greatest functional
contribution to the phenotypic differences observed between
Dupuytren’s fascia and non-diseased fascia
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fascia and Dupuytren’s fascia biopsies revealed miR-181b-
5p as the only microRNA with a statistically significant
enrichment greater than 1.4 fold in the Dupuytren’s fascia.
The lack of statistically significant microRNAs is attribut-
able largely to the variability in the adjacent fascia biopsy
specimens (Dupuytren vs control phenotype); therefore
we compared upregulated microRNAs in each paired
sample using a Venn diagram method (Fig. 5). This ana-
lysis showed an enrichment of anti-fibrotic extracellular
matrix targeting microRNAs in two of the adjacent fascia
specimens relative to their matched Dupuytren’s biopsy
[23–29, 68, 69]. However the single adjacent fascia speci-
men that clustered with the diseased Dupuytren’s fascia
during unsupervised hierarchical clustering (specimen
“A”) did not show enrichment in collagen/extracellular
matrix targeting microRNAs. These findings support its
preferential clustering with the Dupuytren’s fascia and
indicate that its molecular phenotype more closely
resembles that of diseased fascia rather than control fascia
despite its grossly normal appearance. A comparison of
adjacent and control fascial biopsies also did not reveal
any microRNAs with a statistically significant enrichment
in the adjacent fascia, again highlighting the variability of
the adjacent fascia biopsies. There were however seven
microRNAs (miR-335-3p, miR-128, miR-224-5p, miR-28-
5p, miR-191-5p, miR-423-3p, and miR-181a-5p) with a
statistically significant upregulation in the controls. Two
of these seven microRNAs, miR-335-3p, and miR-181a-5p
are also validated extracellular matrix targeting micro-
RNAs [30, 31, 70–72]. Their enrichment in external
control specimens supports their previously described role
as anti-fibrotic microRNAs, and is a reflection of a partial
disease phenotype in the adjacent fascia specimens. These
findings highlight the potential utility of microRNAs as
biomarkers to confirm diagnosis and define optimal surgi-
cal margins to ensure all diseased fascia is removed at the
Table 1 MicroRNAs differentially expressed between Dupuytren’s and control palmar fascia
MicroRNAs enriched in Dupuytren’s fascia MicroRNAs enriched in external control fascia
microRNA Differential read count microRNA Differential read count
Dupuytren’s vs external control fascia External control vs Dupuytren’s fascia
hsa-miR-21-5p 104875.60 hsa-miR-10b-5p 25385.58
hsa-miR-320a 65390.83 hsa-miR-26a-5p 21275.22
hsa-miR-22-3p 45760.50 hsa-miR-126-3p 18657.06
hsa-miR-378a-3p 33330.36 hsa-let-7 g-5p 16538.33
hsa-let-7b-5p 16107.56 hsa-miR-99a-5p 16257.13
hsa-miR-134 9518.18 hsa-miR-101-3p 9984.21
hsa-miR-127-3p 8325.92 hsa-let-7f-5p 8123.18
hsa-miR-23a-3p 5829.286 hsa-let-7a-5p 7884.75
hsa-miR-370 5474.795 hsa-miR-27a-3p 7553.27
hsa-miR-378c 4531.18 hsa-miR-27b-3p 7262.95
hsa-miR-152 3644.90 hsa-miR-30d-5p 4436.03
hsa-miR-145-5p 3469.33 hsa-miR-29a-3p 3611.05
hsa-miR-181a-5p 2433.00 hsa-miR-125a-5p 3042.29
hsa-miR-381-3p 2361.47 hsa-miR-10a-5p 2033.13
hsa-miR-452-5p 1804.42 hsa-miR-26b-5p 1971.30
hsa-miR-409-3p 1804.10 hsa-let-7d-5p 1153.14
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time of surgery. It also implicates microRNAs as potential
therapeutic targets/agents to prevent as well as treat active
fibrotic disease.
Computational microRNA target prediction
MicroRNAs have the ability to inhibit a large number of
target genes by binding to sequence specific 3’UTR
regions of target mRNAs, inhibiting their translation and
promoting their degradation [73]. To confirm preferen-
tial targeting of pathways linked to extracellular matrix
synthesis and cellular proliferation, and to identify novel
pathways that are regulated by microRNAs in Dupuyt-
ren’s disease, we performed computational target predic-
tion using the combinatorial miRNA target prediction
tool ComiR [18, 19] (Additional file 3: Table S3). This
program uses computational targets generated using
miRanda, PITA, TargetScan, and mirSVR, and deter-
mines gene targets for a set of microRNAs taking into
account the relative expression of each microRNA in a
set of samples. We compared microRNA gene targets
between Dupuytren’s fascia, and control fascia only,
since adjacent fascia may represent an intermediate state
between Dupuytren’s tissue and unaffected external con-
trol tissue. Abundant, differentially expressed micro-
RNAs with an average expression level of at least 100
normalized reads per million in either the Dupuytren’s
or control specimens were evaluated.
Analysis with ComiR identified 6685 genes that were
computationally predicted to be inhibited by microRNAs
enriched in control fascia (p < 0.05). In the Dupuytren’s
fascia there were 4969 genes computationally predicted
to be targeted by enriched microRNAs. Functional anno-
tation clustering using David 6.7 for the top 3000 most
heavily targeted genes in control and diseased fascia
identified candidate molecular pathways regulated by
microRNAs (Fig. 6). ComiR analysis confirmed preferen-
tial targeting of extracellular matrix synthesis and cellu-
lar proliferation in the control palmar fascia. Notable
Fig. 5 A venn diagram showing a comparison of microRNAs upregulated (fold change > 2) in patient matched Dupuytren’s fascia and adjacent fascia
biopsies. It is notable that there are no microRNAs commonly upregulated in any of the patient matched biopsies in either the Dupuytren’s or the
adjacent fascia, highlighting the heterogeneity (Dupuytren’s vs control phenotype) of the adjacent fascia biopsies. During unsupervised hierarchical
clustering analysis (Fig. 2) specimen “a” preferentially clustered with Dupuytren’s fascia, thus intraoperative examination of surgical tissue may not be
able to reliably differentiate between diseased and non-diseased fascia at the molecular level. It is notable that adjacent fascia specimens “b” and “c”,
which cluster with control fascia, both show enrichment in known collagen targeting microRNAs (highlighted in grey), which are depleted in
specimen “A”
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Fig. 6 a Functional annotation clustering using DAVID 6.7 was performed for microRNA genes targets enriched in Dupuytren’s fascia using ComiR
target prediction. Functional gene clustering shows preferential targeting and inhibition of pathways linked to lipid synthesis and metalloprotease
inhibitors in diseased Dupuytren’s fascia. b Functional annotation clustering using DAVID 6.7 was performed for microRNA genes targets enriched in
control palmar fascia using ComiR target prediction. Functional gene clustering shows preferential targeting and inhibition of pathways linked to
collagen and extracellular matrix synthesis, inflammation and immune response, as well as cell division and mitosis in non-diseased control palmar fascia
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microRNA inhibited pathways in control fascia included
wound healing (enrichment score 1.99), extracellular
matrix synthesis (enrichment score 1.48), cytokine pro-
duction (enrichment score 1.48), mitochondrion (enrich-
ment score 1.39), muscle cell differentiation (enrichment
score 1.37), cell cycle (enrichment score 1.3), epithelial
cell differentiation and keratinization (enrichment score
1.29), and collagen and laminin production (enrichment
score 1.16). In diseased Dupuytren’s fascia, microRNAs
are most notably predicted to inhibit pathways linked to
lipid-binding/lipoproteins (enrichment score 2.16), cad-
herins (enrichment score 1.97), fatty acid biosynthesis
(enrichment score 1.61), and metalloenzyme inhibitors
(enrichment score 1.16).
RT-qPCR validation of microRNA gene targets
Since extracellular matrix synthesis is predicted to be
inhibited by microRNAs enriched in control palmar fascia,
we examined the expression of collagens, the primary con-
stituents of extracellular matrix in palmar fascia. We per-
formed RT-qPCR to evaluate the expression of selected
collagens linked to fibrosis in diseased and non-diseased
tissues (Fig. 7). We then examined which of these colla-
gens were preferentially targeted for microRNA inhibition
in control palmar fascia based on ComiR analysis (Table 2).
RT-qPCR of fibrosis related collagens shows that collagens
predicted to be targeted by microRNA inhibition in
controls are enriched in Dupuytren’s fascia, while colla-
gens with less microRNA targeting (e.g. COL15A1 and
COL18A1) do not show statistically significant differences
in expression between diseased and non-diseased tissue.
These results show that the expression of collagen target-
ing microRNAs inversely correlates with the expression of
fibrosis related collagens in palmar fascia.
Previous studies have implicated alterations in Wnt
and TGFβ signaling in the pathogenesis of Dupuytren’s
disease [7, 74, 75]. To determine if microRNAs regulate
either of these pathways, we evaluated the expression of
mRNAs associated with these two signaling pathways
using RT-qPCR (Fig. 8). TGFBR2 and WNT5A were the
only two genes to show statistically significant differ-
ences in expression between the Dupuytren’s and control
palmar fascia. TGFBR2 paradoxically showed increased
expression in the control fascia, enrichment inconsistent
with its known fibrosis promoting affects. WNT5A was
the only gene to show a statistically significant enrich-
ment in the Dupuytren’s fascia. However microRNA tar-
get prediction indicates that WNT5A is preferentially
inhibited by microRNAs enriched in Dupuytren’s fascia,
indicating that microRNA regulation is unlikely to be
driving the increased expression of WNT5A in diseased
palmar fascia. These findings suggest that microRNAs,
which promote mRNA degradation, do not play a major
role in post-transcriptional regulation of WNT and TGFβ
Fig. 7 RT-qPCR evaluation of ten selected collagens in Dupuytren’s and control palmar fascia are shown. COL8A1 and COL15A1 are the only collagens
that do not show a statistically significant enrichment in Dupuytren’s fascia. These findings are in accordance with ComiR predictions, which show that
these two exhibit the lowest degree of inhibitory microRNA targeting in control fascia
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signaling pathways in the terminal stages of Dupuytren’s
disease.
Discussion
Previous studies using microarrays, which give relative
abundance of mRNAs and microRNAs, have been used
to study differences in microRNA expression between
Dupuytren’s and non-diseased palmar fascia [76, 77]. In
comparison with microarrays, RNA-seq provides a
broader dynamic range for accurate quantification of dif-
ferentially expressed transcripts [78]. Therefore in this
investigation we applied RNA-seq technology to quantify
the expression of all known human microRNAs in
Dupuytren’s and control palmar fascia biopsies. Our ini-
tial assessment of microRNA sequencing data from the
Dupuytren’s and control palmar fascia biopsies using un-
biased unsupervised hierarchical clustering confirmed
previous findings with microarray analysis, showing that
diseased and non-diseased specimens cluster based upon
their microRNA profiles [76, 77].
In comparison with our study, Mosakhani et al. ap-
plied microarrays to evaluate microRNA expression in
Dupuytren’s tissue samples [77]. Our studies confirmed
enrichment of microRNAs miR-10b, miR-7f, miR-101,
miR-26a, miR-26b, miR-29a, and miR-30 in non-
diseased palmar fascia samples. A large number of
microRNAs identified as being enriched in either the
Dupuytren’s or control fascia were not found to be sta-
tistically significant in our analysis. Interestingly, miR-21
the most abundant microRNA in all samples from our
study, in contrary to their results, was found to be
enriched in Dupuytren’s samples rather than control
samples. These differences may be attributable to the fact
that microarrays can become saturated with abundantly
expressed transcripts, making fold change comparisons
unreliable. Additional considerations include the use of
fewer control samples (N = 4), and the fact that each of
the control samples were taken from the transverse carpal
ligament, which is deep to the true palmar fascia which
gives rise to the Dupuytren’s cords. Two of the control
samples were also collected from patients with acute hand
trauma, which could also significantly alter microRNA
profiles. Satish et al. compared transcriptomes of fibro-
blasts derived from Dupuytren’s fascia, palmar fascia, and
the transverse carpal ligament using microarrays. They
found that fibroblasts from the Dupuytren’s fascia and pal-
mar fascia were more similar to one another than either
one was to the transverse carpal ligament derived fibro-
blasts [76]. Thus the comparisons used in our study com-
paring palmar fascia to Dupuytren’s fascia are likely to be
highly informative.
The microRNAs identified in this investigation that are
enriched in control fascia encompass known, as well
uncharacterized, but potentially novel anti-fibrotic micro-
RNAs. Established anti-fibrotic microRNAs identified in
our analysis include let-7 [23–25], miR-29a-3p [26], miR-
26b-5p, miR-30d-5p [28, 29], miR-27b-3p [30, 31], miR-
10a-5p [33], miR-26a-5p [37–40], miR-101-3p [41–44],
miR-27a-3p and miR-10b-5p [45]. Additional enriched
microRNAs (miR-126-3p [46–52], miR-99a-5p [53–59],
miR-125a-5p [60–64], and miR-139-5p [65–67]) have
been shown to affect proliferation in cancer, and may
regulate the fibroproliferative activity seen in Dupuytren’s
disease. Synergistic activation or inhibition of these micro-
RNAs, which will be investigated in future studies, may
collectively permit the potent attenuation or activation of
fibrosis for therapeutic applications.
Table 2 Collagens targeted by microRNAs enriched in control
palmar fascia - ComiR target prediction shows that the majority
of collagens are preferentially inhibited by microRNAs
enriched in control fascia compared with Dupuytren’s fascia.
In our analysis of collagen expression using RT-qPCR, COL8A1
and COL15A1 were the only collagens that did not show a
statistically significant increase in Dupuytren’s fascia. Notably
these collagens also exhibited the lowest degree of microRNA
targeting
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Previous studies have looked at single microRNA tar-
gets, and have implicated microRNAs as regulatory factors
in Wnt and TGFβ signaling. In this study we used a com-
prehensive approach simultaneously taking into account
the microRNA targets for all abundant, differentially
expressed microRNAs. This analysis suggests a loss of
microRNAs that target extracellular matrix synthesis in
Dupuytren’s disease. MicroRNA target prediction also
showed strong correlation with mRNA expression as
demonstrated by the expression of extracellular matrix
forming collagens. In contrast to previous studies, we did
not observe strong evidence for microRNA regulation of
Wnt or TGFβ signaling pathways. This finding was also
exemplified by RT-qPCR expression data that did not
show major difference in the expression of gene tran-
scripts implicated in either of these signaling pathways.
These findings do not rule out the possibility of post
translational mechanisms (e.g. protein phosphorylation) in
propagating either of these pathways. It is also important
to note that the tissues examined in this investigation are
from patients with advanced disease requiring surgical
resection. Collagen synthesis and deposition is characteris-
tic of late stage Dupuytren’s disease where the diseased
cords are in the process of consolidating. These studies do
Fig. 8 A RT-qPCR screen for fibrosis associated mRNAs linked to Wnt and TGFβ signaling are shown. This analysis reveals a statistically significant
upregulation of WNT5A in Dupuytren’s fascia, and a paradoxical upregulation of TGFBR2 in control fascia. WNT5A is predicted to be downregulated by
microRNAs enriched in Dupuytren’s disease based on ComiR analysis, thus WNT5A upregulation is unlikely to be mediated solely by microRNA
regulatory. In accordance with ComiR target predictions, we do not observe strong evidence for direct microRNA regulation of TGFβ and Wnt
signaling pathways in Dupuytren’s disease
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not exclude the possibility that earlier stages of disease
may still be mediated by over activation of Wnt or TGFβ
signaling pathways.
Our analytical approach takes into account the fact
that large changes in the expression of a small group of
microRNAs may have a more dramatic change on cellu-
lar phenotype, than small changes in a large number of
different microRNAs because of the lack of coordinated
mRNA inhibition by differentially expressed microRNAs.
This study also supports the concept that abundantly
expressed microRNAs are well suited for fine tune regu-
lation of genes translated from plentiful transcripts such
as collagens and other extracellular matrix constituents.
Since extracellular matrix targeting microRNAs are con-
stitutively present in large quantities, they can act as a
buffer to fine tune extracellular matrix synthesis. This is
in stark contrast to alternative regulatory elements such
as transcription factors that produce an all or nothing
response by directly activating or suppressing mRNA
transcription. Analysis of the impact of broad spectrum
microRNA targeting, rather than an evaluation of their
effects on individual target genes may give greater
insight into the important role that microRNAs play in
regulating cellular processes.
Conclusions
The main finding of this study is that microRNA profiles
show distinct expression patterns that differentiate dis-
eased Dupuytren’s and healthy palmar fascia. The micro-
RNAs enriched in healthy tissue show preferential
targeting of collagens and extracellular matrix proteins.
This finding is strongly supported by the fact that differ-
ential collagen expression as determined by RT-qPCR, is
strongly related to the degree of predicted microRNA
targeting.
The microRNAs characterized in this investigation
have the potential to serve as disease biomarkers that
can help guide surgical management by determining op-
timal surgical margins during open fasciectomy. Novel
RNA-therapeutics that are currently in development,
also have the potential to target disease specific micro-
RNAs and prophylactically prevent disabling fibrosis
minimizing the need for invasive surgical treatments.
Fibrosis related microRNAs may also play important
regulatory roles in other disorders of fibrosis including
scleroderma, idiopathic pulmonary fibrosis, as well as
scarring and wound healing.
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